US4217344A
(en)
|
1976-06-23 |
1980-08-12 |
L'oreal |
Compositions containing aqueous dispersions of lipid spheres
|
US4235871A
(en)
|
1978-02-24 |
1980-11-25 |
Papahadjopoulos Demetrios P |
Method of encapsulating biologically active materials in lipid vesicles
|
US4186183A
(en)
|
1978-03-29 |
1980-01-29 |
The United States Of America As Represented By The Secretary Of The Army |
Liposome carriers in chemotherapy of leishmaniasis
|
US4261975A
(en)
|
1979-09-19 |
1981-04-14 |
Merck & Co., Inc. |
Viral liposome particle
|
US4485054A
(en)
|
1982-10-04 |
1984-11-27 |
Lipoderm Pharmaceuticals Limited |
Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
|
US4501728A
(en)
|
1983-01-06 |
1985-02-26 |
Technology Unlimited, Inc. |
Masking of liposomes from RES recognition
|
US4946787A
(en)
|
1985-01-07 |
1990-08-07 |
Syntex (U.S.A.) Inc. |
N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
|
US5049386A
(en)
|
1985-01-07 |
1991-09-17 |
Syntex (U.S.A.) Inc. |
N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
|
US4897355A
(en)
|
1985-01-07 |
1990-01-30 |
Syntex (U.S.A.) Inc. |
N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
|
US4797368A
(en)
|
1985-03-15 |
1989-01-10 |
The United States Of America As Represented By The Department Of Health And Human Services |
Adeno-associated virus as eukaryotic expression vector
|
US4774085A
(en)
|
1985-07-09 |
1988-09-27 |
501 Board of Regents, Univ. of Texas |
Pharmaceutical administration systems containing a mixture of immunomodulators
|
US4837028A
(en)
|
1986-12-24 |
1989-06-06 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
US5013556A
(en)
|
1989-10-20 |
1991-05-07 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
US5264618A
(en)
|
1990-04-19 |
1993-11-23 |
Vical, Inc. |
Cationic lipids for intracellular delivery of biologically active molecules
|
WO1991017424A1
(en)
|
1990-05-03 |
1991-11-14 |
Vical, Inc. |
Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
|
US5173414A
(en)
|
1990-10-30 |
1992-12-22 |
Applied Immune Sciences, Inc. |
Production of recombinant adeno-associated virus vectors
|
US5587308A
(en)
|
1992-06-02 |
1996-12-24 |
The United States Of America As Represented By The Department Of Health & Human Services |
Modified adeno-associated virus vector capable of expression from a novel promoter
|
US6027726A
(en)
|
1994-09-30 |
2000-02-22 |
Inex Phamaceuticals Corp. |
Glycosylated protein-liposome conjugates and methods for their preparation
|
US5846946A
(en)
|
1996-06-14 |
1998-12-08 |
Pasteur Merieux Serums Et Vaccins |
Compositions and methods for administering Borrelia DNA
|
DE69836092T2
(en)
|
1997-10-24 |
2007-05-10 |
Invitrogen Corp., Carlsbad |
RECOMBINATORY CLONING USING NUCLEAR FACILITIES WITH RECOMBINATION CENTERS
|
US6534261B1
(en)
|
1999-01-12 |
2003-03-18 |
Sangamo Biosciences, Inc. |
Regulation of endogenous gene expression in cells using zinc finger proteins
|
DE60334618D1
(en)
|
2002-06-28 |
2010-12-02 |
Protiva Biotherapeutics Inc |
METHOD AND DEVICE FOR PREPARING LIPOSOMES
|
BRPI0513390A
(en)
|
2004-07-16 |
2008-05-06 |
Us Gov Health & Human Serv |
AIDS vaccines containing cmv / r nucleic acid constructs
|
JP5639338B2
(en)
|
2005-07-27 |
2014-12-10 |
プロチバ バイオセラピューティクス インコーポレイティッド |
Liposome production system and production method
|
CA2711179A1
(en)
|
2007-12-31 |
2009-07-16 |
Nanocor Therapeutics, Inc. |
Rna interference for the treatment of heart failure
|
SI2506857T1
(en)
|
2009-12-01 |
2018-08-31 |
Translate Bio, Inc. |
Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
|
EP3578205A1
(en)
|
2010-08-06 |
2019-12-11 |
ModernaTX, Inc. |
A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
|
US9405700B2
(en)
|
2010-11-04 |
2016-08-02 |
Sonics, Inc. |
Methods and apparatus for virtualization in an integrated circuit
|
US8691750B2
(en)
|
2011-05-17 |
2014-04-08 |
Axolabs Gmbh |
Lipids and compositions for intracellular delivery of biologically active compounds
|
IL307511A
(en)
|
2011-06-08 |
2023-12-01 |
Shire Human Genetic Therapies |
Lipid nanoparticle compositions and methods for mrna delivery
|
US10323236B2
(en)
|
2011-07-22 |
2019-06-18 |
President And Fellows Of Harvard College |
Evaluation and improvement of nuclease cleavage specificity
|
WO2013039857A1
(en)
|
2011-09-12 |
2013-03-21 |
modeRNA Therapeutics |
Engineered nucleic acids and methods of use thereof
|
EP2755693A4
(en)
|
2011-09-12 |
2015-05-20 |
Moderna Therapeutics Inc |
Engineered nucleic acids and methods of use thereof
|
CA3165769A1
(en)
|
2011-12-07 |
2013-06-13 |
Alnylam Pharmaceuticals, Inc. |
Biodegradable lipids for the delivery of active agents
|
US11021737B2
(en)
|
2011-12-22 |
2021-06-01 |
President And Fellows Of Harvard College |
Compositions and methods for analyte detection
|
WO2013116126A1
(en)
|
2012-02-01 |
2013-08-08 |
Merck Sharp & Dohme Corp. |
Novel low molecular weight, biodegradable cationic lipids for oligonucleotide delivery
|
LT2800811T
(en)
|
2012-05-25 |
2017-09-11 |
The Regents Of The University Of California |
Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
|
KR101656237B1
(en)
|
2012-10-23 |
2016-09-12 |
주식회사 툴젠 |
Composition for cleaving a target DNA comprising a guide RNA specific for the target DNA and Cas protein-encoding nucleic acid or Cas protein, and use thereof
|
PL3138910T3
(en)
|
2012-12-06 |
2018-01-31 |
Sigma Aldrich Co Llc |
Crispr-based genome modification and regulation
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
WO2014093709A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
|
KR20150105634A
(en)
|
2012-12-12 |
2015-09-17 |
더 브로드 인스티튜트, 인코퍼레이티드 |
Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation
|
EP3825401A1
(en)
|
2012-12-12 |
2021-05-26 |
The Broad Institute, Inc. |
Crispr-cas component systems, methods and compositions for sequence manipulation
|
IL239317B
(en)
|
2012-12-12 |
2022-07-01 |
Broad Inst Inc |
Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
|
PT2784162E
(en)
|
2012-12-12 |
2015-08-27 |
Broad Inst Inc |
Engineering of systems, methods and optimized guide compositions for sequence manipulation
|
PL2931898T3
(en)
|
2012-12-12 |
2016-09-30 |
Le Cong |
Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
|
WO2014093694A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
|
MX2015007743A
(en)
|
2012-12-17 |
2015-12-07 |
Harvard College |
Rna-guided human genome engineering.
|
US9777262B2
(en)
|
2013-03-13 |
2017-10-03 |
President And Fellows Of Harvard College |
Mutants of Cre recombinase
|
US20160184458A1
(en)
|
2013-03-14 |
2016-06-30 |
Shire Human Genetic Therapies, Inc. |
Mrna therapeutic compositions and use to treat diseases and disorders
|
US9267135B2
(en)
|
2013-06-04 |
2016-02-23 |
President And Fellows Of Harvard College |
RNA-guided transcriptional regulation
|
CN105492611A
(en)
|
2013-06-17 |
2016-04-13 |
布罗德研究所有限公司 |
Optimized CRISPR-CAS double nickase systems, methods and compositions for sequence manipulation
|
WO2014204727A1
(en)
|
2013-06-17 |
2014-12-24 |
The Broad Institute Inc. |
Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
|
CN113425857A
(en)
|
2013-06-17 |
2021-09-24 |
布罗德研究所有限公司 |
Delivery and use of CRISPR-CAS systems, vectors and compositions for liver targeting and therapy
|
EP3597755A1
(en)
|
2013-06-17 |
2020-01-22 |
The Broad Institute, Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using viral components
|
KR20160044457A
(en)
|
2013-06-17 |
2016-04-25 |
더 브로드 인스티튜트, 인코퍼레이티드 |
Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation
|
US10329587B2
(en)
|
2013-07-10 |
2019-06-25 |
President And Fellows Of Harvard College |
Orthogonal Cas9 proteins for RNA-guided gene regulation and editing
|
US11306328B2
(en)
|
2013-07-26 |
2022-04-19 |
President And Fellows Of Harvard College |
Genome engineering
|
US9163284B2
(en)
|
2013-08-09 |
2015-10-20 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a Cas9 nuclease
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
US9322037B2
(en)
|
2013-09-06 |
2016-04-26 |
President And Fellows Of Harvard College |
Cas9-FokI fusion proteins and uses thereof
|
US9737604B2
(en)
|
2013-09-06 |
2017-08-22 |
President And Fellows Of Harvard College |
Use of cationic lipids to deliver CAS9
|
US9340799B2
(en)
|
2013-09-06 |
2016-05-17 |
President And Fellows Of Harvard College |
MRNA-sensing switchable gRNAs
|
LT3066201T
(en)
|
2013-11-07 |
2018-08-10 |
Editas Medicine, Inc. |
Crispr-related methods and compositions with governing grnas
|
US10787684B2
(en)
|
2013-11-19 |
2020-09-29 |
President And Fellows Of Harvard College |
Large gene excision and insertion
|
US9074199B1
(en)
|
2013-11-19 |
2015-07-07 |
President And Fellows Of Harvard College |
Mutant Cas9 proteins
|
WO2015089486A2
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
|
BR112016013547A2
(en)
|
2013-12-12 |
2017-10-03 |
Broad Inst Inc |
COMPOSITIONS AND METHODS OF USE OF CRISPR-CAS SYSTEMS IN NUCLEOTIDE REPEAT DISORDERS
|
WO2015089427A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Crispr-cas systems and methods for altering expression of gene products, structural information and inducible modular cas enzymes
|
US20150165054A1
(en)
|
2013-12-12 |
2015-06-18 |
President And Fellows Of Harvard College |
Methods for correcting caspase-9 point mutations
|
EP3450553B1
(en)
|
2014-03-24 |
2019-12-25 |
Translate Bio, Inc. |
Mrna therapy for treatment of ocular diseases
|
CN114344275A
(en)
|
2014-07-02 |
2022-04-15 |
川斯勒佰尔公司 |
Encapsulation of messenger RNA
|
US10077453B2
(en)
|
2014-07-30 |
2018-09-18 |
President And Fellows Of Harvard College |
CAS9 proteins including ligand-dependent inteins
|
EP3178935B1
(en)
|
2014-08-06 |
2022-12-21 |
Toolgen Incorporated |
Genome editing using campylobacter jejuni crispr/cas system-derived rgen
|
WO2016035044A1
(en)
|
2014-09-05 |
2016-03-10 |
Vilnius University |
Programmable rna shredding by the type iii-a crispr-cas system of streptococcus thermophilus
|
WO2016049258A2
(en)
|
2014-09-25 |
2016-03-31 |
The Broad Institute Inc. |
Functional screening with optimized functional crispr-cas systems
|
US11071790B2
(en)
|
2014-10-29 |
2021-07-27 |
Massachusetts Eye And Ear Infirmary |
Method for efficient delivery of therapeutic molecules in vitro and in vivo
|
EP3212772A4
(en)
|
2014-10-31 |
2018-10-03 |
Massachusetts Institute of Technology |
Delivery of biomolecules to immune cells
|
WO2016094874A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Escorted and functionalized guides for crispr-cas systems
|
WO2016100974A1
(en)
|
2014-12-19 |
2016-06-23 |
The Broad Institute Inc. |
Unbiased identification of double-strand breaks and genomic rearrangement by genome-wide insert capture sequencing
|
US9790490B2
(en)
|
2015-06-18 |
2017-10-17 |
The Broad Institute Inc. |
CRISPR enzymes and systems
|
EP3929287A3
(en)
|
2015-06-18 |
2022-04-13 |
The Broad Institute, Inc. |
Crispr enzyme mutations reducing off-target effects
|
EP3666895A1
(en)
|
2015-06-18 |
2020-06-17 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
US10648020B2
(en)
|
2015-06-18 |
2020-05-12 |
The Broad Institute, Inc. |
CRISPR enzymes and systems
|
WO2017015545A1
(en)
|
2015-07-22 |
2017-01-26 |
President And Fellows Of Harvard College |
Evolution of site-specific recombinases
|
US10612011B2
(en)
|
2015-07-30 |
2020-04-07 |
President And Fellows Of Harvard College |
Evolution of TALENs
|
IL297017A
(en)
|
2015-10-08 |
2022-12-01 |
Harvard College |
Multiplexed genome editing
|
ES2914225T3
(en)
|
2015-10-16 |
2022-06-08 |
Modernatx Inc |
Modified phosphate bond mRNA cap analogs
|
WO2017070633A2
(en)
|
2015-10-23 |
2017-04-27 |
President And Fellows Of Harvard College |
Evolved cas9 proteins for gene editing
|
WO2017223127A1
(en)
|
2016-06-21 |
2017-12-28 |
President And Fellows Of Harvard College |
Frequency-based modulation of diverse species in a nucleic acid library
|
SG11201900907YA
(en)
|
2016-08-03 |
2019-02-27 |
Harvard College |
Adenosine nucleobase editors and uses thereof
|
EP3507364A4
(en)
|
2016-08-31 |
2020-05-20 |
President and Fellows of Harvard College |
Methods of generating libraries of nucleic acid sequences for detection via fluorescent in situ sequencing
|
AU2017371324A1
(en)
|
2016-12-09 |
2019-07-11 |
Massachusetts Institute Of Technology |
CRISPR effector system based diagnostics
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
US11104937B2
(en)
|
2017-03-15 |
2021-08-31 |
The Broad Institute, Inc. |
CRISPR effector system based diagnostics
|
US11021740B2
(en)
|
2017-03-15 |
2021-06-01 |
The Broad Institute, Inc. |
Devices for CRISPR effector system based diagnostics
|
US10968257B2
(en)
|
2018-04-03 |
2021-04-06 |
The Broad Institute, Inc. |
Target recognition motifs and uses thereof
|
SG11202011015QA
(en)
|
2018-05-15 |
2020-12-30 |
Flagship Pioneering Innovations V Inc |
Fusosome compositions and uses thereof
|
KR20210044213A
(en)
|
2018-07-10 |
2021-04-22 |
알리아 테라퓨틱스 에스.알.엘. |
Vesicles for trace-free delivery of guide RNA molecules and/or guide RNA molecule/RNA-guided nuclease complex(s) and methods of production thereof
|
CA3106162A1
(en)
|
2018-07-13 |
2020-01-16 |
Allele Biotechnology And Pharmaceuticals, Inc. |
Methods of achieving high specificity of genome editing
|
JP2021534798A
(en)
|
2018-08-28 |
2021-12-16 |
フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー |
Methods and compositions for regulating the genome
|
AU2020242032A1
(en)
|
2019-03-19 |
2021-10-07 |
Massachusetts Institute Of Technology |
Methods and compositions for editing nucleotide sequences
|
AU2022283964A1
(en)
|
2021-06-03 |
2023-12-21 |
Prime Medicine, Inc. |
Genome editing compositions and methods for treatment of wilson's disease
|
US20230059368A1
(en)
|
2021-06-15 |
2023-02-23 |
Prime Medicine, Inc. |
Polynucleotide editors and methods of using the same
|
CA3224970A1
(en)
|
2021-07-06 |
2023-01-12 |
Holly A. REES |
Compositions and methods for efficient genome editing
|
WO2023288332A2
(en)
|
2021-07-16 |
2023-01-19 |
Prime Medicine, Inc. |
Genome editing compositions and methods for treatment of wilson's disease
|
WO2023004439A2
(en)
|
2021-07-23 |
2023-01-26 |
Prime Medicine, Inc. |
Genome editing compositions and methods for treatment of chronic granulomatous disease
|
WO2023015318A2
(en)
|
2021-08-05 |
2023-02-09 |
Prime Medicine, Inc. |
Genome editing compositions and methods for treatment of cystic fibrosis
|
WO2023015014A1
(en)
|
2021-08-05 |
2023-02-09 |
Prime Medicine, Inc. |
Genome editing compositions and methods for treatment of myotonic dystrophy
|
WO2023070062A2
(en)
|
2021-10-21 |
2023-04-27 |
Prime Medicine, Inc. |
Genome editing compositions and methods for treatment of usher syndrome type 3
|
WO2023070110A2
(en)
|
2021-10-21 |
2023-04-27 |
Prime Medicine, Inc. |
Genome editing compositions and methods for treatment of retinitis pigmentosa
|
WO2023076898A1
(en)
|
2021-10-25 |
2023-05-04 |
The Broad Institute, Inc. |
Methods and compositions for editing a genome with prime editing and a recombinase
|
WO2023077148A1
(en)
|
2021-11-01 |
2023-05-04 |
Tome Biosciences, Inc. |
Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo
|